Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis 4

Abstract: Aliskiren is an orally active direct renin inhibitor which inhibits the synthesis of angiotensin I by linking to active renin on a deep cleft of its molecular structure, the site of hydrolysis of the Leu10-Val11 bond of angiotensinogen. At variance with angiotensin-converting enzyme (ACE) inhibitors, aliskiren eliminates the main substrate for the ‘escape’ phenomenon (synthesis of angiotensin II from angiotensin I through alternative enzymatic pathways). The possibility that the antihypertensive effect of aliskiren differs from that of ACE inhibitors needs to be proved in specifically designed clinical trials. Over the past 2 years, three studies have been published which directly compared aliskiren with ramipril, in patients with hypertension. We made a pooled analysis of these studies. In order to avoid interference with additional drugs, analysis was restricted to trial periods when the two drugs were given as monotherapy. In each individual study, systolic blood pressure (BP) was slightly lower with aliskiren. Overall, systolic BP was lower with aliskiren than with ramipril (weighted mean dif-ference between the treatments 1.84mmHg; fixed effect model; p< 0.0001; and 1.87mmHg; random effect model; p 0.0055). The standardized mean difference between the treatments was 2.58 (fixed effect model; p< 0.0001) and 2.92 (random effect model; p 0.0017) in favor of aliskiren. Compared with ramipril, aliskiren may have induced a more complete ‘upstream’ inhibition of the reninangiotensinaldosterone system, with consequent greater suppression of angiotensin II. Another potential explanation may be the longer terminal elimination halflife of aliskiren (about 40 hours) compared with ramiprilat (1317 hours). These data provide further evidence that aliskiren monotherapy provides a sustained BP reduction over the 24 hours